3 ms·
To revolutionize drug discovery, you need to solve a number of problems that ML can't really address right now. We do not have well-formed theories of the mole
by dekhn 4y ago
To revolutionize drug discovery, you need to solve a number of problems that ML can't really address right now.
We do not have well-formed theories of the molecular details of many diseases. There is no immediate computational approach that address this defect. The community has had fairly simplified models for some time, and there's a lot of historical belief that by knowing protein structures in details, we can understand the nature of a disease through its molecular etiology, and from that, we can make drugs (either small molecules or biomolecules) that modulate proteins in rational ways to eliminate the disease with a minimum of side effects.
In my mind, much of the problem is similar to modern deep learning compared to previous techniques. Several extremely challenging problems (high accuracy voice recognition, image recognition, object detection) simple were not solvable through the statistical techniques and mental models adopted by the practitioners. It is not abundantly obvious that stupidly simple deep networks can be pretrained on enormous amounts of labelled data, or even unlabelled data, but we didn't even have the ability to know this confidently until we had the right network architectures, enough high quality labelled data, and adequate compute power to train them.
I believe that by starting to think about disease modelling from the same mindset as deep learning (simple models with many parameters, the models don't actually represent the assumed mechanism, large amounts of high quality data, lots of CPU, GPU, and RAM) and also thinking of the disease treatment process in the same way will greatly increase our ability to "understand" and "treat" diseases, while knowing far less about their underlying mechanism that we thought.
A common example is disease/patient stratification. If you've developed drugs that treat disease A, but it turns out later, there are really two diseases, A1 and A2 with different underlying mechanisms but superficially similar exterior symptoms, you'll realize why some percentage of your population didn't get better (and often got worse, given the underlying toxicity of some medicines). If we could just stratify diseases better, and classify patients into the right bins, the effectiveness of medicine will go up (and drugs will get through clinical trials faster/better).
None of this addresses the later-stage issues, such as successfully running all the phases of a clinical trial and the other gauntlets you must pass in order to get a drug FDA-approved.
I would continue to expect marginal improvements for the foreseeable future. But be aware: some companies already have managed to do a good enough job developing new medicines that they routinely create multi-billion-dollar blockbuster drugs year after year after year (my employer, Genentech, is a perfect example of that). It maintains an enormous and well-funded R&D arm that expends untold neurons attempting to understanding disease better even before we start to consider something as "druggable".